Rare Disease Treatment Market (2024 - 2034)
Rare Disease Treatment Market Study by Haematology, Genetic Diseases, Neurological Diseases, Oncology, Infectious Diseases, Inflammatory Diseases, Metabolic Diseases, and Others from 2024 to 2034
Core Findings
FREE CustomizationRare Disease Treatment Market Outlook (2024 to 2034)
Fact.MR’s latest study reveals that the global rare disease treatment market size is forecasted to increase from a value of US$ 182.28 billion in 2024 to US$ 412.59 billion by the end of 2034. Market expansion has been projected at a CAGR of 8.5% from 2024 to 2034.
This market addresses medical conditions that affect a small number of people and are not so common. Given their rarity and complexity, these illnesses-often referred to as orphan diseases-have a cumulative effect on a comparatively small population, which presents a barrier to research and development. The combined prevalence of rare diseases is significant.
Increasing awareness and advocacy efforts, advancements in genetic and molecular research, and the creation of novel therapeutic approaches are some of the factors driving the market's growth. Due to developments in the field of genomics, precision medicine is emerging, providing new opportunities for targeted therapies catering to the unique genetic profiles of patients suffering from uncommon diseases.
Key Market Growth Drivers
- Primary factor for increase in the demand for rare disease treatment is the rising funding for research and development initiatives aimed at creating novel therapies for uncommon illnesses.
- Advancements in personalized medicine, genomics, and biotechnology are opening up opportunities for therapeutic discovery.
- Pharmaceutical companies are encouraged to develop treatments for rare diseases by favorable regulatory policies, such as fast-track approvals and orphan drug designations.
- The drug development and commercialization process is streamlined through these incentives.
- Demand for rare disease treatment is rising as a consequence of the use of various distribution channels, including online pharmacies, specialty pharmacies, and hospital pharmacies.
- Government policies that are supportive of the industry's growth are driving factors such as the rise in rare disease cases and vaccination campaigns, along with the launch of new medications and innovative therapeutics.
- Research in rare hemophilia factors and rare neurodegenerative disease treatments are also influencing the market.
| Report Attributes | Details |
|---|---|
| Rare Disease Treatment Market Size (2024E) | US$ 182.28 Billion |
| Forecasted Market Value (2034F) | US$ 412.59 Billion |
| Global Market Growth Rate (2024 to 2034) | 8.5% CAGR |
| Latin America Market Share (2024E) | 8.9% |
| North America Market Share (2024E) | 42% |
| Sales of Originator Drugs (2024E) | US$ 134.84 Billion |
| Key Companies Profiled | Novartis AG; AbbVie; Bristol Myers Squibb; BioMarin; Amgen Inc.; PTC Therapeutics; AstraZeneca; GlaxoSmithKline Plc; Amgen Inc.; Pfizer Inc.; Johnson & Johnson |
What is Responsible for Increase in Rare Disease Treatment Solutions?
“Increasing Government Incentives Promoting Innovation in Healthcare for Improved Outcomes”
The market for rare disease treatment is exhibiting growth in developing countries due to rising demand for better healthcare services, large investments in infrastructure development, and the emergence of innovative practices in the healthcare sector. The demand for treatments for rare diseases is not just seen in developed nations but also in developing nations. The demand for rare disease treatments is rising due to factors such as government incentives to encourage innovation in rare disease treatment management.
What are the Hindrances to Market Growth?
“Limited Patient Pool and Dispersed and Diverse Patient Population”
As rare diseases affect a small fraction of the global population, it can be challenging for treatment providers and researchers to find enough patients who meet the inclusion and exclusion criteria for a given study. The rare disease patient pool is dispersed and diverse in terms of disease subtype, symptoms, stages, and previous medical treatment.
Country-wise Insights
The market for rare disease treatments in North America is projected to expand at a significant pace as a result of the country's high prevalence of rare diseases, the growing number of such patients receiving treatments, and improvements in rare disease treatment management. These are some of the key rare disease treatment market trends in the region.
What is Fueling Expansion of Rare Disease Treatment Market Size in the United States?
“Robust Healthcare System for Identification and Management of Rare Diseases”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 63.37 Billion |
| Growth Rate (2024 to 2034) | 8% CAGR |
| Projected Value (2034F) | US$ 137.12 Billion |
High prevalence of rare diseases in the United States, including Huntington's disease, spina bifida, fragile X syndrome, Guillain-Barre syndrome, Crohn's disease, cystic fibrosis, and Duchenne muscular dystrophy, as well as the existence of a strong healthcare system for the diagnosis and treatment of rare diseases, are expected to contribute to the country’s dominance in the market for rare disease treatments.
- Around 200,000 people in the United States are being affected by a rare disease, according to the Food and Drug Administration.
- The burden of rare diseases is roughly 10 times greater than that of mass-market diseases on a per-patient per year (PPPY) basis, according to an article published in 2022 in Chiesi Global Rare Diseases.
- According to the Genetic and Rare Diseases (GARD) Information Center, one in every 10 Americans (or 30 million people) has a rare disease, with approximately 7,000 known rare diseases as of May 2022.
Which Factors are Conducive to Market Growth in Brazil?
“Government Healthcare Policies Supporting Efficient Management of Rare Diseases”
| Attribute | Brazil |
|---|---|
| Market Value (2024E) | US$ 6.09 Billion |
| Growth Rate (2024 to 2034) | 9.4% CAGR |
| Projected Value (2034F) | US$ 14.89 Billion |
Demand for rare disease treatment in Brazil is estimated to reach US$ 6.08 billion in 2024. Brazil accounts for 38% of the rare disease treatment market share in Latin America in 2024. Brazil's healthcare system is made up of three private components, where patients pay for their medical care, a small paid health insurance component, and a large public component called SUS (Sistema Único de Saúde).
According to the Commonwealth Fund, approximately 75% of the population is dependent on SUS, which does not currently offer sufficient coverage for procedures involving genetic medicines. Brazil has developed a policy that is suitable for managing rare diseases, indicating the introduction of medical genetics into the public health system, thus resulting in rare disease treatment market growth in the country.
Category-wise Insights
Rare disease treatments are primarily categorized based on therapeutic area into genetic diseases, neurological diseases, oncology, infectious diseases, inflammatory diseases, metabolic diseases, pulmonary diseases, kidney diseases, musculoskeletal diseases, endocrine diseases, and topical diseases. Genetically mutated diseases occupy a leading market share of 28% in 2024.
Why are Rare Disease Treatment Solutions Widely Adopted for Addressing Genetic Disorders?
“Increased Public Awareness of Genetic Conditions and Advancements in Diagnostic Procedures”
| Attribute | Genetic Disease |
|---|---|
| Segment Value (2024E) | US$ 51.66 Billion |
| Growth Rate (2024 to 2034) | 8.7% CAGR |
| Projected Value (2034F) | US$ 118.76 Billion |
Many individuals with rare diseases are affected by genetic mutations. This reflects the wide spectrum of such conditions. A 2021 trial identified 791 potential orphan drug candidates, with 192 patients experiencing genetic issues. The genetic testing market, integral to rare disease diagnosis, is expanding, driven by factors including increased public awareness, technological advancements, and improved accessibility.
Why Do Originator Drugs Account for a Leading Market Share?
“Sales of Originators Driven by Patent Protection and Ability to Offer Specialized Care”
| Attribute | Originator Drugs |
|---|---|
| Segment Value (2024E) | US$ 134.84 Billion |
| Growth Rate (2024 to 2034) | 8.9% CAGR |
| Projected Value (2034F) | US$ 316.96 Billion |
Originator drugs are protected by a patent, giving the pharmaceutical company that discovered them exclusive rights. These medications are used to treat rare diseases for which there were no prior effective therapies. Since rare diseases are not commonly observed, effective treatment options are limited.
This gap is filled by originator medications, which offer focused care for particular hereditary or uncommon disorders.
Medication for spinal muscular atrophy, Gaucher disease, and cystic fibrosis are a few examples. Different classifications of originator drugs exist, such as biologics (complex molecules derived from living organisms) and organic compounds. Treatment providers for rare genetic disorders are increasingly utilizing biologics, such as monoclonal antibodies.
Competitive Landscape
Key players in the rare disease treatment market are Novartis AG, AbbVie, Bristol Myers Squibb, BioMarin, Amgen Inc., PTC Therapeutics, AstraZeneca, GlaxoSmithKline Plc, Amgen Inc., Pfizer Inc., and Johnson & Johnson.
- As per the Canadian Organization for Rare Disorders (CORD) Report 2021, approximately 1 in 12 individuals in Canada is impacted by rare diseases annually, with approximately 80% attributed to genetic mutations. Due to the substantial prevalence of rare diseases in the country, demand for effective treatment solutions is projected to rise over the forecast period.
- A study reported that as of May 2022, 30 million Americans, or 1 in 10 of the population, suffered from a rare disease, and there are about 7,000 known rare diseases, according to the Genetic and Rare Diseases (GARD) Information Center.
- In November 2023, the Union Health Ministry of India introduced generic medications to support the care and treatment of four conditions: Wilson's disease, Gaucher's disease, Tyrosinemia-Type 1, and Dravet- Lennox-Gastaut syndrome. This initiative aims to alleviate the burden on patients with rare diseases across India, offering these medications at a fraction of their current market prices, ranging from 60 to 100 times less expensive.
Segmentation of Rare Disease Treatment Market Research
-
By Therapeutic Area :
- Hematology
- Genetic Diseases
- Neurological Diseases
- Oncology
- Infectious Diseases
- Inflammatory Diseases
- Metabolic Diseases
- Pulmonary Diseases
- Kidney Diseases
- Musculoskeletal Diseases
- Endocrine Diseases
- Topical Diseases
-
By Drug Type :
- Originator Drugs
- Generic Drugs
-
By Drug Class :
- Biologics
- Organic Compounds
-
By Mode of Administration :
- Injectables
- Oral
-
By Distribution Channel :
- Hospital Pharmacies
- Specialty Treatment Pharmacies
- Retail Pharmacies
-
By Region :
- North America
- Europe
- Latin America
- East Asia
- South Asia & Oceania
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Market Background
- 5. Market Context
- 6. Global Market - Pricing Analysis
- 7. Global Market Value Analysis 2018 to 2023 and Forecast, 2024 to 2034
- 8. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Therapeutic Area
- 8.1. Hematology
- 8.2. Genetic Diseases
- 8.3. Neurological Diseases
- 8.4. Oncology
- 8.5. Infectious Diseases
- 8.6. Inflammatory Diseases
- 8.7. Metabolic Diseases
- 8.8. Pulmonary Diseases
- 8.9. Kidney Diseases
- 8.10. Musculoskeletal Diseases
- 8.11. Endocrine Diseases
- 8.12. Topical Diseases
- 9. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Drug Type
- 9.1. Originator Drugs
- 9.2. Generic Drugs
- 10. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Drug Class
- 10.1. Biologics
- 10.2. Organic Compounds
- 11. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Mode of Administration
- 11.1. Injectables
- 11.2. Oral
- 12. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Distribution Channel
- 12.1. Hospital Pharmacies
- 12.2. Specialty Treatment Pharmacies
- 12.3. Retail Pharmacies
- 13. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Region
- 13.1. North America
- 13.2. Latin America
- 13.3. Europe
- 13.4. East Asia
- 13.5. South Asia
- 13.6. Oceania
- 13.7. Middle East and Africa (MEA)
- 14. North America Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 15. Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 16. Middle East and Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 17. Rest of the World Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 18. Key and Emerging Countries Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 19. Market Structure Analysis
- 20. Competition Analysis
- 20.1. Novartis AG
- 20.2. AbbVie
- 20.3. Bristol Myers Squibb
- 20.4. BioMarin
- 20.5. Amgen Inc.
- 20.6. PTC Therapeutics
- 20.7. AstraZeneca
- 20.8. GlaxoSmithKline Plc
- 20.9. Amgen Inc.
- 20.10. Pfizer Inc.
- 20.11. Johnson & Johnson
- 21. Assumptions and Acronyms Used
- 22. Research Methodology
List Of Table
Table 01: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Therapeutic Area
Table 02: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Type
Table 03: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Class
Table 04: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Mode of Administration
Table 05: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel
Table 06: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Mode of Administration Age Group
Table 07: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Region
Table 08: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 09: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Therapeutic Area
Table 10: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Class
Table 11: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Type
Table 12: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Mode of Administration
Table 13: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel
Table 14: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 15: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Therapeutic Area
Table 16: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Class
Table 17: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Type
Table 18: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Mode of Administration
Table 19: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel
Table 20: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 21: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Therapeutic Area
Table 22: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Class
Table 23: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Type
Table 24: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Mode of Administration
Table 25: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel
Table 26: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Therapeutic Area
Table 27: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Class
Table 28: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Type
Table 29: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Mode of Administration
Table 30: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel
List Of Figures
Figure 01: Global Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 02: Global Market Absolute $ Opportunity, 2024 to 2034
Figure 03: Global Market Share Analysis (%), By Therapeutic Area, 2024 & 2034
Figure 04: Global Market Y-o-Y Analysis (%), By Therapeutic Area, 2024 to 2034
Figure 05: Global Market Attractiveness Analysis By Therapeutic Area, 2024 to 2034
Figure 06: Global Market Share Analysis (%), By Drug Type, 2024 & 2034
Figure 07: Global Market Y-o-Y Analysis (%), By Drug Type, 2024 to 2034
Figure 08: Global Market Attractiveness Analysis By Drug Type, 2024 to 2034
Figure 09: Global Market Share Analysis (%), By Drug Class, 2024 & 2034
Figure 10: Global Market Y-o-Y Analysis (%), By Drug Class, 2024 to 2034
Figure 11: Global Market Attractiveness Analysis By Drug Class, 2024 to 2034
Figure 12: Global Market Share Analysis (%), By Mode of Administration, 2024 & 2034
Figure 13: Global Market Y-o-Y Analysis (%), By Mode of Administration, 2024 to 2034
Figure 14: Global Market Attractiveness Analysis By Mode of Administration, 2024 to 2034
Figure 15: Global Market Share Analysis (%), By Distribution Channel, 2024 & 2034
Figure 16: Global Market Y-o-Y Analysis (%), By Distribution Channel , 2024 to 2034
Figure 17: Global Market Attractiveness Analysis, By Distribution Channel, 2024 to 2034
Figure 18: Global Market Share Analysis (%), By Mode of Administration Age Group, 2024 & 2034
Figure 19: Global Market Y-o-Y Analysis (%), By Mode of Administration Age Group, 2024 to 2034
Figure 20: Global Market Attractiveness Analysis By Mode of Administration Age Group, 2024 to 2034
Figure 21: Global Market Share Analysis (%), By Region, 2024 & 2034
Figure 22: Global Market Y-o-Y Analysis (%), By Region, 2024 to 2034
Figure 23: Global Market Attractiveness Analysis, By Region, 2024 to 2034
Figure 24: North America Market Value Share, By Therapeutic Area, 2024 (E)
Figure 25: North America Market Value Share, By Drug Classs 2024 (E)
Figure 26: North America Market Value Share, By Drug Type, 2024 (E)
Figure 27: North America Market Value Share, By Mode of Administration, 2024 (E)
Figure 28: North America Market Value Share, By Distribution Channel, 2024 (E)
Figure 29: North America Market Value Share, By Country, 2024 (E)
Figure 30: North America Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 31: North America Market Attractiveness Analysis By Therapeutic Area, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis By Drug Class, 2024 to 2034
Figure 33: North America Market Attractiveness Analysis By Drug Type, 2024 to 2034
Figure 34: North America Market Attractiveness Analysis By Mode of Administration, 2024 to 2034
Figure 35: North America Market Attractiveness Analysis By Distribution Channel, 2024 to 2034
Figure 36: North America Market Attractiveness Analysis By Country, 2024 to 2034
Figure 37: Europe Market Value Share, By Therapeutic Area, 2024 (E)
Figure 38: Europe Market Value Share, By Drug Classs 2024 (E)
Figure 39: Europe Market Value Share, By Drug Type, 2024 (E)
Figure 40: Europe Market Value Share, By Mode of Administration, 2024 (E)
Figure 41: Europe Market Value Share, By Distribution Channel, 2024 (E)
Figure 42: Europe Market Value Share, By Country, 2024 (E)
Figure 43: Europe Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 44: Europe Market Attractiveness Analysis By Therapeutic Area, 2024 to 2034
Figure 45: Europe Market Attractiveness Analysis By Drug Class, 2024 to 2034
Figure 46: Europe Market Attractiveness Analysis By Drug Type, 2024 to 2034
Figure 47: Europe Market Attractiveness Analysis By Mode of Administration, 2024 to 2034
Figure 48: Europe Market Attractiveness Analysis By Drug Type, 2024 to 2034
Figure 49: Europe Market Attractiveness Analysis By Country, 2024 to 2034
Figure 50: Middle East and Africa Market Value Share, By Therapeutic Area, 2024 (E)
Figure 51: Middle East and Africa Market Value Share, By Drug Class, 2024 (E)
Figure 52: Middle East and Africa Market Value Share, By Drug Type, 2024 (E)
Figure 53: Middle East and Africa Market Value Share, By Mode of Administration, 2024 (E)
Figure 54: Middle East and Africa Market Value Share, By Distribution Channel, 2024 (E)
Figure 55: Middle East and Africa Market Value Share, By Country, 2024 (E)
Figure 56: Middle East and Africa Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 57: Middle East and Africa Market Attractiveness Analysis By Therapeutic Area, 2024 to 2034
Figure 58: Middle East and Africa Market Attractiveness Analysis By Drug Class, 2024 to 2034
Figure 59: Middle East and Africa Market Attractiveness Analysis By Drug Type, 2024 to 2034
Figure 60: Middle East and Africa Market Attractiveness Analysis By Mode of Administration, 2024 to 2034
Figure 61: Middle East and Africa Market Attractiveness Analysis By Distribution Channel, 2024 to 2034
Figure 62: Middle East and Africa Market Attractiveness Analysis By Country, 2024 to 2034
Figure 63: Rest of the World Market Value Share, By Therapeutic Area, 2024 (E)
Figure 64: Rest of the World Market Value Share, By Drug Classs 2024 (E)
Figure 65: Rest of the World Market Value Share, By Drug Type, 2024 (E)
Figure 66: Rest of the World Market Value Share, By Mode of Administration, 2024 (E)
Figure 67: Rest of the World Market Value Share, By Distribution Channel, 2024 (E)
Figure 68: Rest of the World Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 69: Rest of the World Market Attractiveness Analysis By Therapeutic Area, 2024 to 2034
Figure 70: Rest of the World Market Attractiveness Analysis By Drug Class, 2024 to 2034
Figure 71: Rest of the World Market Attractiveness Analysis By Drug Type, 2024 to 2034
Figure 72: Rest of the World Market Attractiveness Analysis By Mode of Administration, 2024 to 2034
Figure 73: Rest of the World Market Attractiveness Analysis By Distribution Channel, 2024 to 2034
Figure 74: United States Market Value Share, By Therapeutic Area, 2024 & 2034
Figure 75: United States Market Value Share, By Drug Class, 2024 & 2034
Figure 76: United States Market Value Share, By Drug Type, 2024 & 2034
Figure 77: United States Market Value Share, By Mode of Administration Age Group, 2024 & 2034
Figure 78: United States Market Value Share, By Distribution Channel, 2024 & 2034
Figure 79: United States Market Value Analysis (US$ Mn), 2024 & 2034
Figure 80: Canada Market Value Share, By Therapeutic Area, 2024 & 2034
Figure 81: Canada Market Value Share, By Drug Class, 2024 & 2034
Figure 82: Canada Market Value Share, By Drug Type, 2024 & 2034
Figure 83: Canada Market Value Share, By Mode of Administration Age Group, 2024 & 2034
Figure 84: Canada Market Value Share, By Distribution Channel, 2024 & 2034
Figure 85: Canada Market Value Analysis (US$ Mn), 2024 & 2034
Figure 86: United Kingdom Market Value Share, By Therapeutic Area, 2024 & 2034
Figure 87: United Kingdom Market Value Share, By Drug Class, 2024 & 2034
Figure 88: United Kingdom Market Value Share, By Drug Type, 2024 & 2034
Figure 89: United Kingdom Market Value Share, By Mode of Administration Age Group, 2024 & 2034
Figure 90: United Kingdom Market Value Share, By Distribution Channel, 2024 & 2034
Figure 91: United Kingdom Market Value Analysis (US$ Mn), 2024 & 2034
Figure 92: Germany Market Value Share, By Therapeutic Area, 2024 & 2034
Figure 93: Germany Market Value Share, By Drug Class, 2024 & 2034
Figure 94: Germany Market Value Share, By Drug Type, 2024 & 2034
Figure 95: Germany Market Value Share, By Mode of Administration Age Group, 2024 & 2034
Figure 96: Germany Market Value Share, By Distribution Channel, 2024 & 2034
Figure 97: Germany Market Value Analysis (US$ Mn), 2024 & 2034
Figure 98: France Market Value Share, By Therapeutic Area, 2024 & 2034
Figure 99: France Market Value Share, By Drug Class, 2024 & 2034
Figure 100: France Market Value Share, By Drug Type, 2024 & 2034
Figure 101: France. Market Value Share, By Mode of Administration Age Group, 2024 & 2034
Figure 102: France Market Value Share, By Distribution Channel, 2024 & 2034
Figure 103: France Market Value Analysis (US$ Mn), 2024 & 2034
Figure 104: Italy Market Value Share, By Therapeutic Area, 2024 & 2034
Figure 105: Italy Market Value Share, By Drug Class, 2024 & 2034
Figure 106: Italy Market Value Share, By Drug Type, 2024 & 2034
Figure 107: Italy Market Value Share, By Mode of Administration Age Group, 2024 & 2034
Figure 108: Italy Market Value Share, By Distribution Channel, 2024 & 2034
Figure 109: Italy Market Value Analysis (US$ Mn), 2024 & 2034
Figure 110: Spain Market Value Share, By Therapeutic Area, 2024 & 2034
Figure 111: Spain Market Value Share, By Drug Class, 2024 & 2034
Figure 112: Spain Market Value Share, By Drug Type, 2024 & 2034
Figure 113: Spain Market Value Share, By Mode of Administration Age Group, 2024 & 2034
Figure 114: Spain Market Value Share, By Distribution Channel, 2024 & 2034
Figure 115: Spain Market Value Analysis (US$ Mn), 2024 & 2034
Figure 116: GCC Countries. Market Value Share, By Therapeutic Area, 2024 & 2034
Figure 117: GCC Countries Market Value Share, By Drug Class, 2024 & 2034
Figure 118: GCC Countries Market Value Share, By Drug Type, 2024 & 2034
Figure 119: GCC Countries Market Value Share, By Mode of Administration, 2024 & 2034
Figure 120: GCC Countries Market Value Share, By Distribution Channel, 2024 & 2034
Figure 121: GCC Countries Market Value Analysis (US$ Mn), 2024 & 2034
Figure 122: South Africa Market Value Share, By Therapeutic Area, 2024 & 2034
Figure 123: South Africa Market Value Share, By Drug Class, 2024 & 2034
Figure 124: South Africa Market Value Share, By Drug Type, 2024 & 2034
Figure 125: South Africa Market Value Share, By Mode of Administration Age Group, 2024 & 2034
Figure 126: South Africa Market Value Share, By Distribution Channel, 2024 & 2034
Figure 127: South Africa Market Value Analysis (US$ Mn), 2024 & 2034
- Frequently Asked Questions -
How big is the rare disease treatment market in 2024?
The global market for rare disease treatment is estimated at US$ 182.28 Billion in 2024.
What is the value of the rare disease treatment market in the United States?
The United States is estimated to have a market valuation of US$ 63.37 billion in 2024.
What is the market size of Latin America in 2024?
The market in Latin America is estimated to reach US$ 16.13 billion in 2024.
Which type of disease accounts for a high market share?
The treatment of genetic diseases account for around 28% market share.
Which distribution channel is responsible for high revenue generation?
Revenue from specialty treatment pharmacies is estimated at US$ 93.37 billion in 2024.
What is the market value of Brazil in 2024?
Brazil is projected to account for a market value of US$ 6.09 billion in 2024.
Related Reports
Rare Disease Treatment Market